Poietis, billed as the first 4D bioprinting company, has announced the commercialisation of its new range of Next Generation Bioprinting systems (NGB). The NGB systems aim to cover all tissue engineering needs, from research to clinical batches production.
Concept image only
For a number of years, Poietis has been investing in the development of its NGB 4D bioprinting platform to meet the development and production needs of human biological tissues. The company is involved in three target markets: in vitro tissue models as an alternative to animal experimentation in dermo-cosmetics, pharmaceutical research and regenerative medicine.
The company aims to establish a new standard in living tissue manufacturing by enabling users, researchers and clinicians, to design and bioprint tissues with cellular resolution. With this commercial launch, Poietis wants to provide tissue engineering stakeholders with new bioprinting solutions covering all needs, from research in biology and bioengineering to the production of clinical batches.
This new bioprinting platform NGB offers promising perspectives as the clinical and industrial applications of regenerative medicine are growing, when conventional methods of tissue engineering are still limited regarding standardisation of manufacturing processes and in the functionality of the tissues produced.
Largely inspired by the principles of the 4.0 Industry, the new platform integrates automation and robotics technologies, coupled with numerous online sensors - including cell microscopy - and Artificial Intelligence processing. In addition, it now integrates all bioprinting techniques (laser, extrusion, inkjet by micro-valve), a world's first in the bioprinting market.
"We have upgraded the NGB platform to an automated robotic system to improve the standardisation of manufacturing processes and the functionality of biological tissues," said Fabien Guillemot, President and CSO of Poietis. "The combination of multimodal bioprinting with the acquisition and the online processing of printed cell images at cellular resolution will also ensure that what we design is what we print" he added.
"In parallel with our first applicative developments on bioprinted tissues for in vitro models, we continue to evolve our business model to meet the expectations of tissue engineering specialists and biology researchers commented Bruno Brisson, Co-Founder and Business Development Director of Poietis.